{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:05:43Z","timestamp":1794492343451,"version":"4.9.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.euroneuro.2025.11.012","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:44:55Z","timestamp":1766079895000},"page":"112735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy of xanomeline and xanomeline trospium in the treatment of cognitive impairment: A systematic review of preclinical and clinical trials"],"prefix":"10.1016","volume":"103","author":[{"given":"Kyle","family":"Valentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1021-6227","authenticated-orcid":false,"given":"Bianca","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7996-6687","authenticated-orcid":false,"given":"Bethany","family":"Waisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6457-0086","authenticated-orcid":false,"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4064-5588","authenticated-orcid":false,"given":"Hana","family":"Ballum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.11.012_bib0001","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/s41398-017-0002-9","article-title":"Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity","volume":"7","author":"Ahnaou","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0002","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/sj.npp.1300151","article-title":"The muscarinic M1\/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys","volume":"28","author":"Andersen","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0003","series-title":"Enabling Discovery, Development, and Translation of Treatments for Cognitive Dysfunction in Depression: Workshop Summary","author":"Bain","year":"2015"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0004","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145710001549","article-title":"The M\u2081\/M\u2084 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia","volume":"14","author":"Barak","year":"2011","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fpsyg.2016.00705","article-title":"Brain oscillatory correlates of altered executive functioning in positive and negative symptomatic schizophrenia patients and healthy controls","volume":"7","author":"Berger","year":"2016","journal-title":"Front. Psychol"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0006","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13670-018-0234-4","article-title":"Recent advances in cholinergic imaging and cognitive decline-revisiting the cholinergic hypothesis of dementia","volume":"7","author":"Bohnen","year":"2018","journal-title":"Curr. Geriatr. Rep"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0008","first-page":"3111","article-title":"Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses","volume":"11","author":"Bortolato","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0009","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0010","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results","volume":"240","author":"Breier","year":"2023","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neubiorev.2015.05.011","article-title":"The muscarinic system, cognition and schizophrenia","volume":"55","author":"Carruthers","year":"2025","journal-title":"Neurosci. Biobehav. Rev"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0012","unstructured":"ClinicalTrials.gov [WWW Document], 2025a. URL https:\/\/clinicaltrials.gov\/study\/NCT06951711?intr=Xanomeline%20and%20Trospium%20Chloride&sort=StudyFirstPostDate&rank=1 (accessed 5.28.25a)."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0015","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/cr.2008.292","article-title":"Enhancement of memory function in aged mice by a novel derivative of xanomeline","volume":"18","author":"Cui","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0016","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.bbr.2010.02.023","article-title":"The cholinergic system and depression","volume":"221","author":"Dagyt\u0117","year":"2011","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0017","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1523\/JNEUROSCI.0370-11.2011","article-title":"Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1\/M4 preferring muscarinic receptor agonist xanomeline","volume":"31","author":"Dencker","year":"2011","journal-title":"J. Neurosci"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0018","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","article-title":"Clinical pharmacokinetics of trospium chloride","volume":"44","author":"Doroshyenko","year":"2005","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0019","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jpsychires.2021.02.050","article-title":"High-gamma oscillations as neurocorrelates of ADHD: a MEG crossover placebo-controlled study","volume":"137","author":"Dor-Ziderman","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0020","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41380-018-0219-x","article-title":"Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics","volume":"24","author":"Dulawa","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0021","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.euroneuro.2024.11.013","article-title":"Efficacy, tolerability, and safety of xanomeline trospium chloride for schizophrenia: a systematic review and meta-analysis","volume":"92","author":"Fabiano","year":"2025","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0022","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.123.001854","article-title":"Cognitive-enhancing effects of acetylcholine receptor agonists in group-housed Cynomolgus monkeys who drink ethanol","volume":"389","author":"Galbo-Thomma","year":"2024","journal-title":"J. Pharmacol. Exp. Ther"},{"issue":"11","key":"10.1016\/j.euroneuro.2025.11.012_bib0023","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00002512-200118110-00006","article-title":"Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management","volume":"18","author":"Gauthier","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.euroneuro.2025.03.001","article-title":"Muscarinic acetylcholine receptor agonists in bipolar disorder","volume":"95","author":"Gonz\u00e1lez-Campos","year":"2025","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0025","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/s41386-020-00812-7","article-title":"Modulation of arousal and sleep\/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates","volume":"45","author":"Gould","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0026","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.neurobiolaging.2010.08.015","article-title":"Cholinergic system function and cognition in mild cognitive impairment","volume":"33","author":"Haense","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0027","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/neuro.09.026.2009","article-title":"Cognitive functioning in major depression\u2013a summary","volume":"3","author":"Hammar","year":"2009","journal-title":"Front. Hum. Neurosci"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0028","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0029","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","article-title":"The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials","volume":"182","author":"Horan","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0031","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1007\/s00213-015-4073-0","article-title":"Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice","volume":"232","author":"Hunt","year":"2015","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0032","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.104.075887","article-title":"Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats","volume":"312","author":"Jones","year":"2005","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-023-02400-x","article-title":"Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system","volume":"13","author":"Jones","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0034","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline trospium chloride in schizophrenia: a randomized clinical trial: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0036","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2147\/NDT.S406371","article-title":"Xanomeline trospium and muscarinic involvement in schizophrenia","volume":"19","author":"Kidambi","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0037","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/brain\/awu149","article-title":"High frequency oscillations are associated with cognitive processing in human recognition memory","volume":"137","author":"Kucewicz","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0038","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/070674371405901206","article-title":"Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment","volume":"59","author":"Lam","year":"2014","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0039","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14656566.2024.2334424","article-title":"Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review","volume":"25","author":"Leber","year":"2024","journal-title":"Expert Opin. Pharmacother"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2008.08.009","article-title":"Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine","volume":"596","author":"Li","year":"2008","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0041","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuroscience.2019.07.003","article-title":"In vivo pharmacological comparison of TAK-071, a positive allosteric modulator of muscarinic M1 receptor, and xanomeline, an agonist of muscarinic M1\/M4 receptor, in rodents","volume":"414","author":"Mandai","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0042","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.pain.2011.09.017","article-title":"The M1\/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action","volume":"152","author":"Martino","year":"2011","journal-title":"Pain."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0043","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41380-019-0502-5","article-title":"The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis","volume":"26","author":"McCutcheon","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0044","first-page":"1","article-title":"Schizophrenia-an overview","author":"McCutcheon","year":"2020","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/da.22063","article-title":"Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions: review: cognitive deficits and functional outcomes in MDD","volume":"30","author":"McIntyre","year":"2013","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0046","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archpedi.162.10.929","article-title":"Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents","volume":"162","author":"McIntyre","year":"2008","journal-title":"Arch. Pediatr. Adolesc. Med"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0047","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic drug-related weight gain and its treatment","volume":"181","author":"McIntyre","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0048","doi-asserted-by":"crossref","first-page":"84","DOI":"10.24095\/hpcdp.28.3.01","article-title":"The effect of bipolar I disorder and major depressive disorder on workforce function","volume":"28","author":"McIntyre","year":"2008","journal-title":"Chronic Dis. Can"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0049","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40263-015-0263-x","article-title":"The prevalence, measurement, and treatment of the cognitive dimension\/domain in major depressive disorder","volume":"29","author":"McIntyre","year":"2015","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0050","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyaf015","article-title":"From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1\/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials","volume":"28","author":"Meyer","year":"2025","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0051","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS. Drug Rev."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0052","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0053","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41386-020-00916-0","article-title":"The M1\/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain","volume":"46","author":"Montani","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0054","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.encep.2008.06.014","article-title":"Potentiel d\u2019apprentissage et revalidation cognitive dans la schizophr\u00e9nie","volume":"35","author":"Raffard","year":"2009","journal-title":"Encephale"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0056","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0057","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3565(25)38667-2","article-title":"Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors","volume":"269","author":"Shannon","year":"1994","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0058","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2025.11.012_bib0059","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0060","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ijnp\/pyx032","article-title":"Cognitive impairment in bipolar disorder: treatment and prevention strategies","volume":"20","author":"Sol\u00e9","year":"2017","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0061","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0062","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41398-022-01928-8","article-title":"Existing and emerging pharmacological approaches to the treatment of mania: a critical overview","volume":"12","author":"Sparacino","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0063","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0064","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0065","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1092852924002293","article-title":"The mediational role of cognitive function on occupational outcomes in persons with major depressive and bipolar disorder","volume":"29","author":"Tamura","year":"2024","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0066","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000381523","article-title":"Anticholinergic activity and schizophrenia","volume":"15","author":"Tani","year":"2015","journal-title":"Neurodegener. Dis"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0067","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00213-013-3256-9","article-title":"Acute and chronic effects of the M1\/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats","volume":"231","author":"Thomsen","year":"2025","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0013","unstructured":"ClinicalTrials.gov [WWW Document], 2025b. URL https:\/\/clinicaltrials.gov\/study\/NCT06947941?intr=Xanomeline%20and%20Trospium%20Chloride&sort=StudyFirstPostDate&rank=3 (accessed 5.28.25b)."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0068","unstructured":"TNQ Technologies, 2025. Safety and tolerability of xanomeline and trospium chloride in schizophrenia: pooled results from the 5-week, randomized, double-blind, placebo-controlled EMERGENT trials. Psychiatrist.com."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0069","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pmr.2012.02.007","article-title":"Patient safety considerations in the rehabilitation of the individual with cognitive impairment","volume":"23","author":"Tyson","year":"2012","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0070","article-title":"Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias","volume":"11","author":"van der Westhuizen","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0071","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00213-014-3813-x","article-title":"Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey","volume":"232","author":"Vardigan","year":"2015","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0072","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00002093-199812000-00010","article-title":"Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test battery (CNTB)","volume":"12","author":"Veroff","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0073","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14316","article-title":"Antipsychotic efficacy of KarXT (xanomeline trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study","volume":"83","author":"Weiden","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2025.11.012_bib0074","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","article-title":"Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice","volume":"603","author":"Woolley","year":"2009","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0075","first-page":"1245","article-title":"The impact of cognitive impairment and comorbid depression on disability, health care utilization, and costs","volume":"66","author":"Xiang","year":"2015","journal-title":"Psychiatr. v"},{"issue":"1","key":"10.1016\/j.euroneuro.2025.11.012_bib0076","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40263-019-00688-2","article-title":"Cognitive impairment in patients with bipolar disorder: impact of pharmacological treatment","volume":"34","author":"Xu","year":"2020","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.euroneuro.2025.11.012_bib0077","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J. Urol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25007990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25007990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:05:41Z","timestamp":1767859541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X25007990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":76,"alternative-id":["S0924977X25007990"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.11.012","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of xanomeline and xanomeline trospium in the treatment of cognitive impairment: A systematic review of preclinical and clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112735"}}